Immunomedics Inc. [NASDAQ: IMMU] stock went on a downward path that fall over -7.54% on Thursday, amounting to a one-week price increase of more than 0.43%. Over the last 12 months, IMMU stock rose by 141.32%. The one-year Immunomedics Inc. stock forecast points to a potential upside of 22.68. The average equity rating for IMMU stock is currently 1.90, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $6.88 billion, with 213.25 million shares outstanding and 225.74 million shares in the current float. Compared to the average trading volume of 5.21M shares, IMMU stock reached a trading volume of 3221565 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. We’ll cover the basics of better investing and show you how to give yourself an edge in the market.
GET FREE LESSON outside the norm.
Guru’s Opinion on Immunomedics Inc. [IMMU]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMMU shares is $39.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMMU stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Immunomedics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 05, 2020. While these analysts kept the previous recommendation, Goldman dropped their target price from $5 to $22. The new note on the price target was released on April 24, 2020, representing the official price target for Immunomedics Inc. stock. Previously, the target price had yet another raise from $34 to $60, while H.C. Wainwright kept a Buy rating on IMMU stock.
The Average True Range (ATR) for Immunomedics Inc. is set at 1.67, with the Price to Sales ratio for IMMU stock in the period of the last 12 months amounting to 22944.67. The Price to Book ratio for the last quarter was 34.84, with the Price to Cash per share for the same quarter was set at 2.38.
IMMU Stock Performance Analysis:
Immunomedics Inc. [IMMU] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.43. With this latest performance, IMMU shares dropped by -4.75% in over the last four-week period, additionally plugging by 44.33% over the last 6 months – not to mention a rise of 141.32% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMMU stock in for the last two-week period is set at 46.40, with the RSI for the last a single of trading hit 38.23, and the three-weeks RSI is set at 51.60 for Immunomedics Inc. [IMMU]. The present Moving Average for the last 50 days of trading for this stock 27.90, while it was recorded at 31.65 for the last single week of trading, and 19.62 for the last 200 days.
Insight into Immunomedics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Immunomedics Inc. [IMMU] shares currently have an operating margin of -110114.58. Immunomedics Inc.’s Net Margin is presently recorded at -121081.36.
Return on Total Capital for IMMU is now -79.35, given the latest momentum, and Return on Invested Capital for the company is -88.22. Return on Equity for this stock declined to -133.53, with Return on Assets sitting at -59.54. When it comes to the capital structure of this company, Immunomedics Inc. [IMMU] has a Total Debt to Total Equity ratio set at 103.87. Additionally, IMMU Total Debt to Total Capital is recorded at 50.95, with Total Debt to Total Assets ending up at 41.48. Long-Term Debt to Equity for the company is recorded at 99.80, with the Long-Term Debt to Total Capital now at 48.96.
Reflecting on the efficiency of the workforce at the company, Immunomedics Inc. [IMMU] managed to generate an average of -$975,929 per employee. Receivables Turnover for the company is 2.00 with a Total Asset Turnover recorded at a value of 0.00.Immunomedics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.40 and a Current Ratio set at 8.40.
IMMU Stock EPS
With the latest financial reports released by the company, Immunomedics Inc. posted -0.4/share EPS, while the average EPS was predicted by analysts to be reported at -0.3/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMMU. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Immunomedics Inc. go to 9.20%.
Immunomedics Inc. [IMMU] Insider Position Details
There are presently around $5,861 million, or 78.50% of IMMU stock, in the hands of institutional investors. The top three institutional holders of IMMU stocks are: AVORO CAPITAL ADVISORS LLC with ownership of 24,500,000, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 16,849,782 shares of the stock with an approximate value of $552.34 million in IMMU stocks shares; and BLACKROCK INC., currently with $517.2 million in IMMU stock with ownership of nearly 7.357% of the company’s market capitalization.
118 institutional holders increased their position in Immunomedics Inc. [NASDAQ:IMMU] by around 21,141,070 shares. Additionally, 124 investors decreased positions by around 14,789,920 shares, while 41 investors held positions by with 142,861,837 shares. The mentioned changes placed institutional holdings at 178,792,827 shares, according to the latest SEC report filing. IMMU stock had 34 new institutional investments in for a total of 5,000,682 shares, while 58 institutional investors sold positions of 3,807,480 shares during the same period.